Clinical trials: Neoplasms Recurrence
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00085540
- Testing
- depsipeptide
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
B-cell Lymphoma
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed or refractory CD20-positive aggressive lymphomas Phase I: Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each…
- Trial name
- LeMLAR (NCT01788189)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital, Essen
Relapsed or Refractory Acute Myeloid Leukemia (AML)
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD)…
- Trial name
- NCT06660368
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nasopharyngeal Carcinoma
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone…
- Trial name
- NCT05340491
- Testing
- Toripalimab, Chemotherapy, Intensity modulated radiotherapy
- Where
- 12 sites in China
- Volunteers
- 212 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer.
- Trial name
- NCT00003010
- Testing
- marimastat
- Where
- 25 sites in United States
- Volunteers
- 334 people
- Sponsor
- Eastern Cooperative Oncology Group
Hepatocellular Carcinoma, Recurrent Cancer
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the…
- Conditions
- Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
- Trial name
- NCT04204850
- Testing
- Cabozantinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Recurrent Lung Cancer, Lung Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .
- Trial name
- NCT05632913
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Kidney Cancer, Metastatic Cancer
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00588913
- Testing
- aldesleukin, therapeutic autologous lymphocytes, zoledronic acid
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Tokyo Women's Medical University
Glioblastoma
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Angiopoietin-2 (Ang-2) is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels.
- Trial name
- NCT01225510
- Testing
- PF-04856884
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck
Expansion Trial for Axitinib In Head And Neck Cancer
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02762513
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma, Plasma Cell Neoplasm
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00075608
- Testing
- filgrastim, melphalan, autologous stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Intraocular Melanoma, Melanoma (Skin)
Dendritic Cell Vaccination During Lymphoid Reconstruction
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00313508
- Testing
- Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
This phase II trial studies the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer.
- Conditions
- Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma
- Trial name
- NCT03146650
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01132820
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 87 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent/Advanced Gastric Cancer
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Clinical Indication : HER mutated or HER2 Amplification/Overexpression in Gastric Cancer, 2nd-line Trial Type : Interventional, Open label Treatment Groups : Single arm: Pembrolizumab 200 mg every 3 weeks (Q3W), neratinib at 240…
- Trial name
- NCT05512182
- Testing
- Chemotherapy
- Where
- South Korea
- Sponsor
- Yonsei University
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01716715
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 173 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.